CSO Nils Brünner will retire from Scandion Oncology A/SScandion Oncology A/S has agreed with Nils Brünner that he will leave his pos...
Scandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D OperationsScandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations...
Year-end Report 2020: Scandion Oncology is poised for the futureScandion Oncology A/S (”Scandion Oncology” or “the Company”) hereby publishes...
Nasdaq Stockholm Welcomes Scandion Oncology to the Nasdaq First North Growth MarketStockholm, February 3, 2020 – Nasdaq (Nasdaq: NDAQ) announce...
Scandion Oncology adjusts the PANTAX pancreatic cancer studyScandion Oncology A/S (“Scandion” or the “Company”) has submitted an amendmen...
Scandion Oncology has finalized the first 12 patients in the CORIST studyScandion Oncology A/S (“Scandion” or the “Company”) has completed the first 1...
Scandion Oncology approved for listing on Nasdaq First North Growth Market Sweden on 3 February 2021Scandion Oncology A/S ("Scandion" or the "Company") has applied for and recei...
Scandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to sharesScandion Oncology A/S ("Scandion" or the "Company") has carried out a rights ...
Letter from the CEO: Great progress in 2020 - we are ready for 2021!Dear shareholder in Scandion Oncology, dear subscriber to Scandion Oncology N...
Scandion Oncology A/S – Flagging messageScandion Oncology A/S (”Scandion Oncology” or “the Company”) hereby announces...
